Launch Xaciato in the United States
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 6 May 2022
- Due
- 31 Dec 2022
- Delivered
- October 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We're looking forward to potential Q4 launch of this product in the U.S.”
What we found
Evidence strength A What the grades mean
The company announced a potential Q4 2022 launch, but later filings confirm the product was actually launched in October 2023.
-
A Organon & Co. 10-Q filed 2023-11-03
“In October 2023, Xaciato was launched in the United States.” ✓ confirmed on the page
Market reaction: the shares moved -6.8% against the S&P 500 over the three sessions around the disclosure (2 Nov 2023 to 7 Nov 2023). What this measures
Checked 21 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Xaciato
- Where
- United States
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Organon & Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-OGN-018902 · Corrections policy